EP Patent

EP3070090B1 — Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile

Assigned to Incyte Holdings Corp · Expires 2018-12-12 · 7y expired

What this patent protects

Patent listed against ruxolitinib-phosphate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3070090B1
Jurisdiction
EP
Classification
—
Expires
2018-12-12
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Holdings Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.